Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ466,5467-0,11
KB0,00
PKN56,756,762,96
Msft1,00
Nokia3,33353,34-0,27
IBM-0,29
Daimler AG57,4357,541,93
PFE2,87
02.12.2020 1:38:32
Indexy online
AD Index online
select
AD Index online
 

  • 01.12.2020
AxoGen (LT3.BE, Berlin)
Závěr k 1.12.2020 Změna (%) Změna (EUR) Objem obchodů (EUR)
12,00 0,00 0,00 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 02.12.2020
Popis společnosti
Obecné informace
Název společnostiAxoGen Inc
TickerAXGN
Kmenové akcie:Ordinary Shares
RICAXGN.O
ISIN-
Prioritní akciePreference Shares
Prioritní akciePreference Shares
Prioritní akciePreference Shares
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.09.2020
Počet zaměstnanců k 31.12.2019 371
Akcie v oběhu k 27.10.2020 40 126 253
MěnaUSD
Kontaktní informace
Ulice13631 Progress Blvd Ste 400
MěstoALACHUA
PSČ32615-9409
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 864 626 817
Fax13864626801

Business Summary: AxoGen, Inc. offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers the AxoTouch Two-Point Discriminator, and AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation; assessing return of sensory, grip and pinch function; evaluating treatment interventions, and providing feedback to patients on nerve function. Its portfolio of products is available in the United States, Canada, the United Kingdom and several European and other countries. The Company's products are used by surgeons during surgical interventions to repair a range of nerve injuries throughout the body.
Financial Summary: BRIEF: For the nine months ended 30 September 2020, AxoGenInc revenues increased 2% to $79.8M. Net loss decreased 20%to $17.8M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Lower net loss reflects General andadministrative decrease of 23% to $18.7M (expense), OtherSales and marketing decrease of 7% to $48.2M (expense).
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Advanced Medical Equipment & Technology - NEC
RBSS2004Medical Equipment, Supplies & Distribution
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICS2007Electromedical Apparatus Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICElectromedical Equipment
SICElectromedical Equipment
SICCommercial Physical Research



  • Poslední aktualizace: 02.12.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerKaren Zaderej5821.05.201830.09.2011
Chief Financial OfficerPeter Mariani5601.03.201601.03.2016
Chief Human Resource OfficerMaria Martinez5229.10.201829.10.2018
Chief Compliance Officer, General CounselBrad Ottinger-01.06.202001.06.2020
Vice President - OperationsMike Donovan55
Vice President - Clinical and Translational SciencesErick DeVinney44
Vice President - Regulatory Affairs and Quality AssuranceMark Friedman6230.09.201130.09.2011
Vice President - Research and DevelopmentAngelo Scopelianos6504.09.201804.09.2018
Chief Strategy and Business Development OfficerIsabelle Billet5829.10.201829.10.2018
Chief Commercial OfficerEric Sandberg5515.02.201915.02.2019